CRL

Charles River Laboratories International, Inc.

$345.80

-2.13%
SectorHealthcareIndustryDiagnostics & ResearchCountryUnited States

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies.

Source: Yahoo Finance
AI summary

Price & performance

1M+0.7%
3M+20.1%
YTD+54.6%
1Y+86.7%
52-week range—
Beta1.40
Full chart and returns against a benchmark

Q-Score

53/ 100

Quality against peers; 50 is the peer median.

Growth50
Risk60
Performance56
Valuation48
Profitability58
Leverage51
Sentiment61
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$4B-0.9%
Net income-$144.3M-750.1%
Net margin-3.6%-4.1 pts
Historical fundamentals

Revenue exposure

47%of revenue from outside the US
United States53%
Europe27%
Canada12%
Regions, segments, customers and suppliers

Valuation

CRLIndustryP/E412.3241.31P/S4.175.66EV/EBITDA42.2731.63P/B5.134.91PEG—3.59
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report, before the open
EPS estimate$2.97
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate